These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?]. Heidemann J; Kucharzik T Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352 [No Abstract] [Full Text] [Related]
25. [Treatment of Crohn disease--with special reference to anti-TNF antibody therapy]. Takazoe M Nihon Naika Gakkai Zasshi; 2001 Dec; 90(12):2494-502. PubMed ID: 11917871 [No Abstract] [Full Text] [Related]
29. Monoclonal antibody therapy of inflammatory bowel disease. van Deventer SJ; Camoglio L Pharm World Sci; 1997 Apr; 19(2):55-9. PubMed ID: 9151342 [TBL] [Abstract][Full Text] [Related]
30. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease]. Michetti P Rev Med Suisse; 2008 Jan; 4(141):187-8. PubMed ID: 18335883 [No Abstract] [Full Text] [Related]
31. Are there predictors of Remicade treatment success or failure? Su C; Lichtenstein GR Adv Drug Deliv Rev; 2005 Jan; 57(2):237-45. PubMed ID: 15555740 [TBL] [Abstract][Full Text] [Related]
32. [Recommendations for patients with Crohn's disease starting treatment with adalimumab: a rapid guide]. Cabriada JL; García Sánchez V; Gomollón F; Hinojosa J; López San Román A; Mendoza JL; Mínguez M; Ricart E; Saro C Gastroenterol Hepatol; 2008 Dec; 31(10):693-7. PubMed ID: 19174086 [No Abstract] [Full Text] [Related]
33. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?]. Domènech E; López San Román A; Garcia-Planella E Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379 [No Abstract] [Full Text] [Related]
34. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease]. Lazebnik LB; Kniazev OV Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233 [No Abstract] [Full Text] [Related]
35. [Anti-TNF antibodies in the treatment of intestinal inflammatory disease]. Hinojosa J Gastroenterol Hepatol; 2000 May; 23(5):250-7. PubMed ID: 10902280 [No Abstract] [Full Text] [Related]
36. Distal esophageal involvement in Crohn disease: short treatment with adalimumab. Musto D; Martorelli L; Cirillo A; Selvaggi F; Esposito P; Russo MI; Riegler G Endoscopy; 2010; 42 Suppl 2():E299. PubMed ID: 21113880 [No Abstract] [Full Text] [Related]